GARP: His20-Asn627, with C-terminal 10*His HQDKVPCKMVDKKVSCQVLGLLQVPSVLPPDTETLDLSGNQLRSILASPLGFYTALRHLDLSTNEISFLQPGAFQALTHLEHLSLAHNRLAMATALSAGGLGPLPRVTSLDLSGNSLYSGLLERLLGEAPSLHTLSLAENSLTRLTRHTFRDMPALEQLDLHSNVLMDIEDGAFEGLPRLTHLNLSRNSLTCISDFSLQQLRVLDLSCNSIEAFQTASQPQAEFQLTWLDLRENKLLHFPDLAALPRLIYLNLSNNLIRLPTGPPQDSKGIHAPSEGWSALPLSAPSGNASGRPLSQLLNLDLSYNEIELIPDSFLEHLTSLCFLNLSRNCLRTFEARRLGSLPCLMLLDLSHNALETLELGARALGSLRTLLLQGNALRDLPPYTFANLASLQRLNLQGNRVSPCGGPDEPGPSGCVAFSGITSLRSLSLVDNEIELLRAGAFLHTPLTELDLSSNPGLEVATGALGGLEASLEVLALQGNGLMVLQVDLPCFICLKRLNLAENRLSHLPAWTQAVSLEVLDLRNNSFSLLPGSAMGGLETSLRRLYLQGNPLSCCGNGWLAAQLHQGRVDVDATQDLICRFSSQEEVSLSHVRPEDCEKGGLKNINGGGSGGGSHHHHHHHHHH Latent TGF-β1: Leu30-Ser390 LSTCKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKS
72-80kDa(GARP), 38-43kDa(Latent), 14kDa(TGF-β1)
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
1. Alessandra Metelli, Mohammad Salem, Caroline H Wallace, Bill X Wu, Anqi Li. Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer. J Hematol Oncol. 2018 Feb 20;11(1):24.
GARP (glycoprotein-A repetitions predominant) is a type I transmembrane cell surface docking receptor for latent transforming growth factor-β (TGF-β) that is abundantly expressed on regulatory T lymphocytes and platelets. By binding to LTGF-β, GARP acts as a docking receptor that concentrates LTGF-β on the cell surface and enhances its final activation. The function of GARP has been extensively studied on regulatory T lymphocytes (Tregs), where it complexes with αVβ8 integrins to release active TGF-β from the surface of the cells. Via this function, GARP was shown to be involved in enhancing the suppressive phenotype of Tregs and in maintaining Treg-mediated peripheral tolerance.
2μg (R: reducing condition).
Immobilized GARP&Latent TGF-β1 Heterotrimer His Tag, Human (Cat. No. UA010685) at 2.0μg/mL (100μL/well) can bind TGFBR2 Fc Chimera, Human (Cat. No. UA010650) with EC50 of 2.53-2.90ng/mL .
您现在的位置：